



Epidermal Growth Factor and Angiotensin II Regulation of Extracellular Signal-Regulated Protein Kinase in Rat Liver Epithelial WB Cells

Li-Jun Yang, Yan-Lin Guo, Oxana Trygankova, Qiu-Yang Li, Judith A. Maloney,*
Melinda Steinhauer and John R. Williamson†

DEPARTMENT OF BIOCHEMISTRY AND BIOPHYSICS, SCHOOL OF MEDICINE, UNIVERSITY OF PENNSYLVANIA,
PHILADELPHIA, PA 19104, U.S.A.

ABSTRACT. Activation of extracellular signal-regulated protein kinase (ERK) is considered essential for mitogenesis. In the present study, rat liver epithelial WB cells were used to investigate the relative roles of Ca^{2+} , protein kinase C (PKC), and protein tyrosine phosphorylation in mitogenesis and activation of the ERK pathway stimulated by epidermal growth factor (EGF) and angiotensin II (Ang II). The sensitivity of the ERK pathway to Ca^{2+} was studied by using 1,2-bis (O-aminophenoxy)ethane-*N,N,N',N'*-tetraacetic acid (BAPTA) to chelate intracellular Ca^{2+} and a low extracellular Ca^{2+} concentration to prevent Ca^{2+} influx. Agonist-induced PKC activation was diminished by inhibition of PKC by GF-109203X (bisindolylmaleimide) or by down-regulation of PKC by long-term treatment of the cells with phorbol myristate acetate (PMA). Our results show that although activation of PKC was critical for mitogenesis induced by Ang II or EGF, the initial activation of ERK by both agonists in these cells was essentially independent of PKC activation and was insensitive to Ca^{2+} mobilization. This is in contrast to the findings in some cell types that exhibit a marked dependency on mobilization of Ca^{2+} and/or PKC activation. On the other hand, an obligatory tyrosine phosphorylation step for activation of ERK was indicated by the use of protein tyrosine kinase inhibitors, which profoundly inhibited the activation of ERK by EGF, Ang II, and PMA. Additional experiments indicated that tyrosine phosphorylation by a cytosolic tyrosine kinase may represent a general mechanism for G-protein coupled receptor mediated ERK activation. *BIOCHEM PHARMACOL* 57;4:425–432, 1999. © 1999 Elsevier Science Inc.

KEY WORDS. rat liver epithelial WB cells; EGF; angiotensin II; MAP kinase; PKC; mitogenesis

MAP kinases are widely expressed protein Ser/Thr kinases [1, 2]. ERK is the best-studied member of the MAP kinase family, and its activation is considered essential for the initiation of mitogenic processes [3, 4]. Upon activation, ERK regulates the activities of a variety of key signal transduction enzymes and transcription factors, which ultimately affect gene expression and mitogenesis [2, 5, 6]. In response to various extracellular stimuli, the ERK signaling pathway can be activated by receptor tyrosine kinases, such as the EGF receptor, or by G-protein coupled receptors, such as the Ang II receptor. Activation of ERK through receptor tyrosine kinases is the best understood of several pathways that link receptor activation to signaling systems

that target nuclear proteins. After ligand binding, the growth factor receptor causes activation of its tyrosine kinase and autophosphorylation of tyrosine residues in the cytoplasmic domain of the receptor. Adapter proteins such as GRB2 and SHC bind to specific phosphotyrosine residues of the receptor via their *src* homology (SH_2) domains and, through the mediation of Sos, a guanine nucleotide exchange factor, cause activation of Ras, which, in turn, phosphorylates and activates the Raf-MEK-ERK kinase cascade [2, 6].

In contrast, the pathways for G-protein coupled receptor-mediated activation of ERK are currently less clear [7, 8]. Several studies have shown that receptors coupled to G_q proteins cause an activation of ERK that can be accounted for, to different extents, by activation of phospholipase $\text{C}\beta$ and subsequent activation of PKC and Ca^{2+} mobilization [9, 10]. Phorbol esters, by directly stimulating PKC, can activate the ERK pathway in many cell types, probably by phosphorylation and activation of Raf-1 [11, 12]. However, the effects of PKC activation are cell type dependent, suggesting different pathways for activation of ERK or the involvement of different PKC isoforms. A similar lack of consistency is also seen in studies on the role of Ca^{2+} in the regulation of MAP kinase, since both Ca^{2+} -dependent and

* Current address: West VA School of Osteopathic Medicine, Lewisburg, WV 24901.

† Corresponding author: Dr. John R. Williamson, Department of Biochemistry and Biophysics, University of Pennsylvania, 37th and Hamilton Walk, Philadelphia, PA 19104. Tel. (215) 898-8785; FAX (215) 898-9918.

‡ Abbreviations: Ang II, angiotensin II; BAPTA, 1,2-bis (O-aminophenoxy)ethane-*N, N, N', N'*-tetraacetic acid; BrdU, bromodeoxyuridine; EGF, epidermal growth factor; ERK, extracellular signal-regulated protein kinase; G-protein, guanine nucleotide-binding regulatory protein; MAP, mitogen-activated protein; MEK, ERK kinase; PMA, phorbol myristate acetate; PKC, protein kinase C; and TCA, trichloroacetic acid.

Received 13 January 1998; accepted 18 August 1998.

-independent pathways for activation of ERK have been reported [13]. Receptors that are coupled to G_i also cause a stimulation of ERK activity, and recent evidence indicates that this effect may be mediated by G-protein $\beta\gamma$ subunits [14–16]. Activation of ERK by the $\beta\gamma$ subunit pathway requires a tyrosine phosphorylation step since it can be blocked by tyrosine kinase inhibitors such as genistein and herbimycin [17, 18]. However, activation of the ERK signaling pathway by G_q -coupled receptors may be less dependent upon activation of a tyrosine kinase upstream of Ras [19, 20]. It is apparent that activation of the ERK pathway can be achieved by several mechanisms in an agonist and cell-dependent manner, and its full activation may need input from several different cellular signaling systems.

WB cells are epithelial cells that were originally isolated from the livers of adult rats. They show a good responsiveness to Ang II and EGF [20, 21]. The signaling pathways in WB cells initiated by these hormones may play important roles in the development of the liver and its functions. In the present study, rat liver WB cells were used to investigate the roles of Ca^{2+} , PKC, and protein tyrosine kinases in the signaling pathways leading to activation of ERK and mitogenesis after stimulation of cells with EGF and Ang II. The data presented here indicate that although PKC activation induced by EGF and Ang II is essential for the mitogenic effect of these hormones in WB cells, activation of PKC and increased cytosolic free Ca^{2+} play a minor role in the overall activation of ERK. On the other hand, ERK activation stimulated by EGF and Ang II was inhibited extensively by the tyrosine kinase inhibitors genistein and herbimycin, suggesting that recruitment of a tyrosine kinase exerts a critical role downstream of receptor activation in WB cells. Together with the findings reported by other investigators, it seems that tyrosine phosphorylation by a cytosolic tyrosine kinase may represent a general mechanism for ERK activation stimulated by various agonists.

MATERIALS AND METHODS

Materials

EGF, anti-ERK2 antibodies, and ERK substrate peptide were purchased from UBI. Fura-2 and BAPTA/AM were obtained from Molecular Probes, and anti-Raf-1 and anti-MEK1/2 antibodies were from Santa Cruz. PMA and Ang II were purchased from Sigma. Genistein, GF-109203X (bisindolylmaleimide), and herbimycin A were obtained from the LC Laboratories.

Cell Culture

WB cells (passage 20–30) were plated onto 100-mm plastic culture plates and maintained in Richter's improved essential medium containing L-glutamine plus 10% fetal bovine serum at 37° in a humidified incubator (5% CO₂, 95% air) until about 80% confluent. Then cells were serum-starved

for 24–48 hr in Richter's medium without fetal bovine serum before treatment with the agonists.

Measurement of DNA Synthesis

DNA synthesis was determined by two methods. In the first method, DNA synthesis was measured by [³H]thymidine incorporation into DNA. Near confluent WB cells were starved for 48 hr and incubated with EGF, Ang II, or PMA for 24 hr. [³H]Thymidine (25 μ Ci/mL) was added 16 hr before the end of the incubation. The cells were quickly washed three times with ice-cold PBS, incubated for 10 min with 2 mL of 10% (w/v) TCA, and washed three times with 2 mL of 95% ethanol. The acid-insoluble pellet was incubated in 800 μ L of 0.2 N NaOH, and the solution was neutralized with HCl. The radioactivity was determined by liquid scintillation counting. In the second method, DNA synthesis was measured by an immunocytochemistry method. Briefly, WB cells were plated onto coverslips in 6-well plates. Near confluent WB cells were starved for 48 hr and incubated with agonists in the presence or absence of GF-109203X for 20 hr. BrdU was added to the culture medium, and cells were incubated for a further 4 hr. BrdU incorporation into proliferating cells was determined using the BrdU staining kit obtained from Calbiochem, as described previously [22].

Cell Lysate Preparation

WB cells were treated with or without agonists for the indicated times, then washed twice with ice-cold PBS, and scraped into cell lysis buffer containing 50 mM HEPES (pH 7.5), 150 mM NaCl, 1 mM Na₃VO₄, 50 mM pyrophosphate, 100 mM NaF, 1 mM EGTA, 1.5 mM MgCl₂, 1% (v/v) Triton X-100, 10% (v/v) glycerol, 10 μ g/mL of aprotinin, 10 μ g/mL of leupeptin, and 1 mM phenylmethylsulfonyl fluoride. The cells were incubated in the lysis buffer for 1 hr at 4°, and then were centrifuged at 15,000 g at 4° for 20 min. The insoluble material was discarded, and the supernatant was designated as whole cell lysate. The protein concentration was determined by the method of Bradford [23], using BSA as the standard.

Protein Kinase Assays

ERK activation was determined either by the gel shift assay using anti-ERK2 antibodies by western-blot analysis, or by a kinase assay using myelin basic protein (MBP) peptide as substrate. In the gel shift assay, the appearance of a slower migrating band on the gel, due to phosphorylation of threonine and tyrosine residues of ERK, was used as an indication of its activation [22]. The kinase activity assay was performed as described [24] with some modifications. The kinase assay buffer contained 20 mM HEPES (pH 7.4), 10 mM MgCl₂, 20 mM glycerophosphate, 1 mM dithiothreitol (DTT), 2 mM EGTA, 0.1 mM sodium orthovanadate, 20 μ M [γ -³²P]ATP (10 Ci/mmol), 10 μ g/mL of

leupeptin, 10 $\mu\text{g}/\text{mL}$ of aprotinin, 1 mg/mL of MBP peptide substrate, and 0.1 g/mL of BSA. The reaction mixtures were incubated for 20 min at 30°, and the reaction was terminated by the addition of 15 μL of 40% TCA (w/v). After centrifugation at 12,000 g for 5 min, 20 μL of supernatant was spotted onto p81 phosphocellulose paper filters, which were washed five times with 1% (v/v) phosphoric acid. After the final wash, the filters were dried and transferred to scintillation vials. The radioactivity was determined in triplicate assays by liquid scintillation counting.

MEK and Raf-1 activities were assayed by an immunocomplex assay method. MEK and Raf-1 were immunoprecipitated with their specific antibodies. The kinase activities were determined using GST-MEK for Raf-1 and GST-ERK2 for MEK as substrates, respectively, as described previously [25].

PKC activities in the cytosol and particulate fractions were determined by measuring the incorporation of ^{32}P from [γ - ^{32}P]ATP into histone H1 in the presence of 40 $\mu\text{g}/\text{mL}$ of phosphatidylserine and 4 $\mu\text{g}/\text{mL}$ of 1,2-dioleoyl-sn-glycerol in a final volume of 50 μL kinase buffer as used for the ERK kinase assay. The reaction was started by adding cell lysate (5 μg of protein). After incubation for 5 min at 30°, the reaction was stopped by the addition of 10 μL of 25% (w/v) TCA; the remaining procedures were the same as described for the ERK activity assay.

Immunoblotting

The protein samples were subjected to SDS-PAGE and transferred onto nitrocellulose membrane. The membrane was first washed for 15 min with PBS containing 0.1% (v/v) Tween 20 (PBST). Nonspecific binding of proteins was blocked with 3% BSA in PBST for 1 hr, followed by washing twice with PBST. Then the membrane was incubated with primary antibodies for 1 hr at room temperature, followed by three washes with PBST. The membrane was incubated with secondary antibodies for 30 min. After washing with PBST, the immunoblots were visualized by the ECL (enhanced chemiluminescence) system.

Measurement of Cytosolic Free Ca^{2+}

Intracellular Ca^{2+} was measured in single cells using fluorescence microscopy, as described previously [26].

RESULTS

Stimulation of DNA Synthesis and Activation of ERK by Ang II, EGF, and PMA

To compare the mitogenic effects of Ang II and EGF, WB cells were incubated in serum-free medium to arrest them at the G_0 stage of the cell cycle and subsequently were treated with the different agonists. As shown in Fig. 1A, Ang II (1 μM) and EGF (100 ng/mL) both stimulated DNA synthesis, as determined by [^3H]thymidine incorporation into DNA. Separate experiments showed that the maximal




FIG. 1. Mitogenic effects of Ang II, EGF, and PMA in WB cells. (A) Quiescent WB cells were incubated without (–PMA) or with 500 nM PMA (+PMA) for 48 hr. PMA (10 nM), Ang II (1 μM), or EGF (100 ng/mL) was added to the medium and incubated for 48 hr. [^3H]Thymidine (2.5 $\mu\text{Ci}/\text{mL}$) was added 16 hr before the termination of the incubation. [^3H]Thymidine incorporation was measured by determining the radioactivity of acid precipitates from cells in a liquid scintillation counter. (B) Quiescent WB cells were stimulated with 1 μM Ang II, 100 ng/mL of EGF, or 10 nM PMA in the presence (+GF) or absence (–GF) of 1 μM GF-109302X for 20 hr. BrdU was added to the medium during the last 4 hr of incubation. The BrdU-positive staining cells were identified and counted under a microscope; 140–160 cells were counted in each group. Results represent the means \pm SEM of five groups of cells.

effects of [^3H]thymidine incorporation were obtained with these concentrations of agonists (data not shown). Interestingly, PMA, a well-characterized pharmaceutical activator of PKC, also showed a mitogenic effect (Fig. 1A), indicating that PKC may be involved in mediating the mitogenic effects of Ang II and EGF. To test this possibility, the PKC pathway was blocked by two methods. It is known that long-term pretreatment of cells with PMA results in PKC degradation and a loss in total PKC activity, a phenomenon known as PKC down-regulation [9, 10]. As shown in Fig. 1A, pretreatment of the cells for 48 hr with PMA prior to acute stimulation totally abolished the mitogenic effect of PMA, indicating the effectiveness of PKC down-regulation. Under these experimental conditions, Ang II-stimulated DNA synthesis was blocked completely, while EGF-stimulated DNA synthesis was attenuated markedly (Fig. 1A). It is possible that the long-term incubation of cells with PMA may have an inhibitory effect on mitogenesis by a mechanism other than down-regula-




FIG. 2. Time course of Ang II- and EGF-mediated activation of ERK in WB cells. Serum-starved WB cells were treated with 1 μ M Ang II or 100 ng/mL of EGF at different time points as indicated. The activation of ERK2 was determined by the mobility shift assay. The lower band indicates the inactive form and the upper band the active form of ERK2. The bar graph represents the total ERK activity obtained with the kinase activity assay method. The basal kinase activity (0 min) was 1420 cpm/1.5 μ g protein. A similar result was obtained in three separate experiments.

tion of PKC. To test this possibility, the cells were incubated with the hormones in the presence of GF-109203X, a specific inhibitor of PKC, which would acutely block PKC activation [18, 24]. As shown in Fig. 1B, PMA-, Ang II- and EGF-stimulated DNA synthesis was almost totally abolished by this treatment. These results imply that activation of PKC plays a critical role in Ang II- and EGF-stimulated mitogenesis in WB cells.

Since the ERK signaling pathway plays a key role in the initiation of DNA synthesis in many cell types [27], the effects of Ang II and EGF on the activation of ERK were examined in WB cells. ERK2 activation was determined by a gel-shift assay, based on the different electrophoretic mobilities of the phosphorylated (active) and unphosphorylated (inactive) kinase. The phosphorylated form of this enzyme is seen as an upper band (retarded mobility) after SDS-PAGE. The time courses of activation of ERK2 by Ang II and EGF are shown in Fig. 2. Both agents activated ERK2, but to different extents; EGF stimulation of WB cells converted almost all of the ERK2 to its active form within 5 min, and the effect lasted for 60 min, whereas Ang II maximally converted about 50% of ERK2 to its active form. The total ERK activity (Fig. 2, bar graph) after EGF and Ang II stimulation was also measured using MBP peptide as the substrate, and the results correlated well with the activation of ERK2 as determined by the gel shift assay method.

Role of PKC in the Activation of ERK Induced by Ang II and EGF

To ascertain that PKC was indeed activated over the same time periods that ERK activity increased after stimulation with EGF or Ang II, both PKC translocation and activity

were examined. It is known that upon activation by various stimuli, PKC translocates from the cytosol to the cell membrane. Therefore, redistribution of PKC has been regarded as an indication of its activation [28]. Stimulation of WB cells with Ang II (5 min), EGF (5 min), or PMA (10 min) caused a decrease of total PKC activity in the cytosolic fraction and a corresponding increase of PKC activity in the particulate fraction (data not shown). These results demonstrate that a redistribution of the PKC isoforms took place within 5 min of stimulation by EGF or Ang II. PKC down-regulation by prolonged treatment of the cells with PMA, or acute inhibition of PKC by GF-109203X, essentially abolished the effects of Ang II and EGF on PKC activation in both the soluble and particulate fractions (data not shown). PKC is encoded by a multiple gene family, and eleven members have been described to date [28]. Immunoblotting using isoform-specific antibodies detected four PKC isoforms (α , δ , ϵ , and ζ) in the whole cell lysate of WB cells [29]. In resting cells, PKC- α , - δ , and - ϵ were present mainly in the cytosol, while PKC- ζ was distributed approximately equally in the cytosol and the particulate fractions. EGF and Ang II treatment increased the amount of PKC- δ and - ϵ in the particulate fraction, but the distributions of - α and - ζ were not affected, as determined by western-blot analysis (data not shown). These results indicate that the EGF- and Ang II-stimulated activation of total PKC may be accounted for by the δ and ϵ isoforms of PKC.

To investigate the role of PKC in Ang II- and EGF-induced activation of ERK, WB cells were incubated with GF-109203X prior to the addition of EGF and Ang II. As shown in Fig. 3, the most pronounced effect of GF-109203X was to inhibit almost entirely the acute activation of ERK by PMA, thereby confirming the effectiveness of GF-109203X in inhibiting PKC under the conditions of the experiments. In contrast, neither EGF- nor Ang II-mediated activation of ERK was affected appreciably by this PKC inhibitor. It is evident, therefore, that during the first hour of ERK activation by EGF and Ang II, PKC plays a minor role in the overall effects of the hormones on ERK activation.

Role of Ca^{2+} in the Activation of ERK by EGF and Ang II

Since Ca^{2+} has been implicated as a potential regulator of the ERK pathway in many cell types, two approaches were used to investigate the Ca^{2+} sensitivity of ERK activation by Ang II and EGF in WB cells. The first method employed BAPTA/AM to increase the Ca^{2+} buffering capacity of the cytosol. As shown in Fig. 4, preincubation of fura-2-loaded WB cells with 5 μ M BAPTA/AM for 30 min did not affect the resting cytosolic free Ca^{2+} but was sufficient to abolish the Ca^{2+} transient induced by Ang II. The EGF-induced Ca^{2+} transient was similarly inhibited by BAPTA/AM pretreatment (data not shown). The second approach was to lower the extracellular free Ca^{2+} concentration to 1–10




FIG. 3. Effects of the PKC inhibitor GF-109203X on the activation of ERK stimulated by EGF, Ang II, and PMA in WB cells. Serum-starved WB cells were pretreated in the absence (-GF-109203X) or presence of 1 μ M GF-109203X (+GF-109203X) for 30 min followed by the addition of 100 ng/mL of EGF, 1 μ M Ang II, and 10 μ M PMA for 5, 5, and 10 min, respectively. The activation of ERK2 was determined by mobility shift (gel) and kinase activity (bar graph) assays. The kinase activity of the control experiment in the absence of GF-109203X (-GF-109203X) was 1600 cpm/1.5 μ g protein. A similar result was obtained in three separate experiments.

μ M by the addition of a 0.1 mM excess of EGTA over Ca^{2+} to the incubation medium immediately prior to hormone addition. This treatment has little effect on the Ang II- or EGF-induced mobilization of intracellular Ca^{2+} , but prevents Ca^{2+} entry and refilling of the internal Ca^{2+} pools. Figure 5 shows that BAPTA/AM or EGTA treatment of the cells had no inhibitory effect on either the Ang II- or EGF-induced activation of ERK. Thus, the ERK signaling pathway initiated by stimulation of either Ang II or the EGF receptors is Ca^{2+} independent in WB cells.




FIG. 4. Effects of BAPTA/AM on the Ang II-induced increase in cytosolic Ca^{2+} . Serum-starved WB cells were pretreated with 5 μ M BAPTA/AM for 30 min prior to stimulation with Ang II. Intracellular Ca^{2+} was measured in fura-2-loaded cells. The trace is from a single cell in a field of cells and represents a typical response from more than 20 cells.




FIG. 5. Effects of BAPTA/AM and EGTA on Ang II- and EGF-induced ERK activation. Serum-starved WB cells were pretreated with 5 μ M BAPTA/AM for 30 min or with a 0.1 mM excess of EGTA over Ca^{2+} for 15 min prior to stimulation with Ang II (1 μ M Ang II, 5 min) or EGF (100 ng/mL, 5 min). DMSO was used for the control experiments. The total ERK activity was determined by the kinase activity assay method. The kinase activity of the control experiment in the absence of BAPTA and EGTA was 1320 cpm/1.5 μ g protein. Values are means \pm SEM for three determinations.

Effect of Protein Tyrosine Kinase Inhibitors on EGF- and Ang II-induced Activation of ERK

Since the maximal ERK activation induced by EGF or Ang II could not be accounted for by PKC activation or Ca^{2+} mobilization, another pathway(s) must be involved in mediating the effects of these hormones on the activation of ERK in WB cells. Tyrosine phosphorylation of components of the Ras-activated protein kinase cascade is thought to be responsible for activation of ERK by growth factors. In the case of EGF-induced activation of ERK, evidence points to the kinase domain of the receptor itself being responsible for the first committed tyrosine phosphorylation step. The identity of a participating tyrosine kinase in the Ang II-induced pathway for activation of ERK is less well established. To determine whether a tyrosine kinase step was involved in Ang II-mediated activation of ERK, WB cells were pretreated with genistein in order to inhibit tyrosine kinase activity prior to the addition of the stimulating agents. Genistein is a widely used protein tyrosine kinase inhibitor [18, 21]. It profoundly inhibited the EGF-induced activation of ERK, as expected, but it also inhibited almost entirely the activation of ERK induced by Ang II (Fig. 6A). These results suggest that a cytosolic tyrosine kinase is activated as a consequence of binding of Ang II to its G-protein coupled receptor. Further experiments showed that genistein did not affect the activities of either immunoprecipitated MEK or ERK *in vitro* (data not shown). To further confirm the involvement of a tyrosine kinase step in Ang II signaling, the cells were stimulated with Ang II in the presence of another protein tyrosine kinase inhibitor, herbimycin A [18]. ERK and its upstream kinases MEK and Raf-1 were immunoprecipitated with their specific antibodies. As shown in Figure 6B, the




FIG. 6. Effects of genistein and herbimycin A on Ang II- and EGF-mediated activation of ERK. (A) Serum-starved WB cells were pretreated with 100 μ M genistein for 30 min prior to the addition of 1 μ M Ang II or 100 ng/mL of EGF for 5 min. The total ERK activity was determined by the kinase activity assay method. The kinase activity of the control experiment in the absence of genistein was 1190 cpm/1.5 μ g protein. A similar result was obtained from at least three repeated experiments. (B) Herbimycin A inhibition of Ang II-induced activation of Raf-1, MEK, and ERK. Quiescent cells were pretreated with or without 1 μ M herbimycin A for 15 min, and then were stimulated with Ang II for 30 min. The kinase activity was determined by analyzing the densitometry of the autoradiograms as described in Materials and Methods. The value in the control experiment was adjusted to 1 unit (arbitrary unit).

activities of all three kinases stimulated by Ang II were attenuated markedly by herbimycin A. This result is consistent with that obtained with the genistein experiment and supports the notion that a tyrosine kinase is involved in mediating the Ang II-stimulated ERK signaling pathway. In addition, it also indicates that the tyrosine kinase acts upstream of the Raf-MEK-ERK cascade.

Effect of Genistein on the Activation of ERK Induced by Other Agonists

To test whether tyrosine phosphorylation by a cytosolic tyrosine kinase may represent a general mechanism for ERK activation, the cells were pretreated with genistein, and stimulated with PMA, which activates ERK in a PKC-dependent manner, or with phenylephrine, vasopressin, or thrombin, which are known to exert their effects through G-protein coupled receptors. In all cases, the activation of ERK by these agonists was inhibited by at least 50% after




FIG. 7. Effects of genistein on the activation of ERK induced by PMA, phenylephrine, vasopressin, and thrombin. Serum-starved WB cells were pretreated with 100 μ M genistein for 30 min prior to the addition of 10 μ M PMA, 10 μ M phenylephrine, 1 μ M vasopressin, or 10 units/mL of thrombin for 5 min. The total ERK activity was determined by the kinase activity assay method. The kinase activity of the control experiment in the absence of genistein was 1240 cpm/1.5 μ g protein. A similar result was obtained from at least three repeated experiments.

treatment of the cells with genistein (Fig. 7). Thus, a tyrosine phosphorylation step seems to be involved in the activation of the ERK pathway mediated by both G-protein coupled receptors and by the PKC signaling pathway.

DISCUSSION

The ERK signaling cascade is a prominent cellular pathway used by many growth factors and hormones to mediate mitogenesis. One of the earliest responses of cells to EGF and Ang II is an activation of PKC and mobilization of intracellular Ca^{2+} as a consequence of activation of PLC- γ and PLC- β [30]. Thus, activation of PKC and increased Ca^{2+} mobilization are thought to initiate important signaling events that contribute to the final physiological effects of EGF and Ang II in different cells. Although it is well established that EGF can activate the ERK signaling pathway through the Ras-Raf-MEK-ERK cascade by its receptor tyrosine kinase activity, it is evident that ERK activity may also be regulated in many other ways. Ras, Raf, PKC, and Ca^{2+} -dependent and -independent activation of ERK has been reported in a variety of cell types [7, 8, 10, 14, 17, 20, 31–39].

In the present study with WB cells, both EGF-mediated and Ang II-mediated activation of ERK were essentially independent of PKC activation. Therefore, the role of PKC activation seems to be insignificant in the early phase of ERK activation in these cells. However, PKC activation is critical for the mitogenic effect of both EGF and Ang II. It is likely, therefore, that PKC exerts its effect on mitogenesis through other components in the signaling pathway rather than by activation of ERK in WB cells. There appears to be a similar lack of consistency for the role of Ca^{2+} in ERK activation. For example, in foreskin fibroblasts and carci-

noma cells, thapsigargin- and ionomycin-induced ERK activation was Ca^{2+} dependent, whereas EGF-induced ERK activation was Ca^{2+} independent, suggesting that in these cells there are two independent pathways capable of activating ERK [13]. In cardiac myocytes and vascular smooth muscle cells, Ang II-induced ERK activation was Ca^{2+} dependent, since chelation of intracellular Ca^{2+} by BAPTA completely inhibited the activation of ERK induced by Ang II [39, 40]. In contrast, the present study demonstrates that in WB cells, short-term activation of ERK by Ang II or EGF was essentially Ca^{2+} independent. This was shown under the two conditions that were minimally invasive to the cell. The first was to incubate the cells with a low concentration of BAPTA/AM, so that the intracellular Ca^{2+} buffering was increased just sufficiently to prevent the Ang II- or EGF-induced Ca^{2+} transient, while the second was to add a 0.1 mM excess of EGTA over Ca^{2+} to the cell medium just prior to the addition of Ang II or EGF. This latter condition allowed an essentially normal Ca^{2+} transient, but no Ca^{2+} entry. Since neither treatment affected the Ang II- or EGF-induced activation of ERK, we can conclude that the transient Ca^{2+} increase was not obligatory for the early activation of ERK.

The fact that neither PKC activation nor Ca^{2+} mobilization could account for the observed ERK activation induced by Ang II and EGF in WB cells indicates that other pathways predominate. Recently, accumulating evidence has shown that activation of ERK mediated by G-protein coupled receptors requires tyrosine phosphorylation events. Cytosolic tyrosine kinases, such as Hck, Lyn, JAK, and some members of c-Src tyrosine kinases, are thought to be recruited and activated by G-protein receptors directly or indirectly upon their activation by ligand binding [41]. In rat liver WB cells and GN4 cells, Ang II activates at least two tyrosine kinases, which are thought to play a critical role in the activation of ERK in a direct Ca^{2+} -independent manner [20]. In agreement with these findings, our results show that tyrosine kinase(s) is not only involved in, but also plays a major role in the activation of ERK induced by Ang II. Using a genetic approach, Wan and coworkers [42] recently found that a non-receptor tyrosine kinase cascade is located upstream of the ERK pathway activated by G-protein coupled receptors. Among these tyrosine kinases, Syc in conjunction with Fyn and Yes can recruit and phosphorylate the adapter molecule SHC, which subsequently assembles the signal complex of SHC/Grb2/Sos and initiates the Raf-MEK-ERK pathway [42]. This model provides a possible explanation for our results in WB cells, which demonstrate that the ERK pathway, when activated by EGF or Ang II, showed a similar sensitivity to inhibition by genistein. It can be concluded that a Ca^{2+} -independent tyrosine phosphorylation step is critical for upstream activation of the Ras-Raf-MEK-ERK cascade initiated by both EGF and Ang II. Tyrosine phosphorylation, through the intrinsic tyrosine kinase activity of the EGF receptor, is required for EGF to activate ERK, while tyrosine phosphorylation through cytosolic tyrosine kinases

seems to play a critical role in the activation of ERK induced by G-protein coupled receptors.

This work was supported by an American Diabetes Association Career Development Award to L.J.Y. and the National Institutes of Health Grant DK-15120 to J.R.W. Y-L.G. is a recipient of National Institute of Health Training Grant DK-07314.

References

1. Pelech SL and Sanghera JS, MAP kinases: Charting the regulatory pathways. *Science* **257**: 1355–1356, 1992.
2. Davis RJ, The mitogen-activated protein kinase signal transduction pathway. *J Biol Chem* **268**: 14553–14556, 1993.
3. Boulton TG, Yancopoulos GS, Gregory JS, Slaughter C, Moomaw C, Hsu J and Cobb MH, An insulin-stimulated protein kinase similar to yeast kinases involved in cell cycle control. *Science* **249**: 64–67, 1990.
4. Boulton TG, Nye SH, Robbins DJ, Ip NY, Radziejewska E, Morgenbesser SD, DePinho RA, Panayotatos N, Cobb MH and Yancopoulos GD, ERKs: A family of protein-serine/threonine kinases that are activated and tyrosine phosphorylated in response to insulin and NGF. *Cell* **65**: 663–675, 1991.
5. Cobb MH and Goldsmith EJ, How MAP kinases are regulated. *J Biol Chem* **270**: 14843–14846, 1995.
6. Karin M and Hunter T, Transcriptional control by protein phosphorylation: Signal transmission from the cell surface to the nucleus. *Curr Biol* **7**: 747–757, 1995.
7. Pace AM, Faure M and Bourne HR, G_{12} -mediated activation of the MAP kinase cascade. *Mol Biol Cell* **6**: 1685–1695, 1995.
8. Crespo P, Xu N, Simonds WF and Gutkind JS, Ras-dependent activation of MAP kinase pathway mediated by G-protein $\beta\gamma$ subunits. *Nature* **369**: 418–420, 1994.
9. Berra E, Diaz-Meco MT, Dominguez I, Municio MM, Sanz L, Lozano J, Chapkin RS and Moscat J, Protein kinase C ζ isoform is critical for mitogenic signal transduction. *Cell* **74**: 555–563, 1993.
10. Booz GW, Dostal DE, Singer HA and Baker KM, Involvement of protein kinase C and Ca^{2+} in angiotensin II-induced mitogenesis of cardiac fibroblasts. *Am J Physiol* **267**: C1308–C1318, 1994.
11. Kolch W, Heidecker G, Kochs G, Hummel R, Vahidi H, Mischak H, Finkenzeller G, Marme D and Rapp UR, Protein kinase C- α activates RAF-1 by direct phosphorylation. *Nature* **364**: 249–252, 1993.
12. Denhardt DT, Signal-transducing protein phosphorylation cascades mediated by Ras/Rho proteins in the mammalian cell: The potential for multiplex signalling. *Biochem J* **318**: 729–747, 1996.
13. Cao TO, Byron KL, Lee K, Villereal M and Rosner MR, Activation of MAP kinases by calcium-dependent and calcium-independent pathways. *J Biol Chem* **267**: 19876–19883, 1992.
14. Faure M, Voyno-Yasenetskaya TA and Bourne HR, cAMP and $\beta\gamma$ subunits of heterotrimeric G proteins stimulate the mitogen-activated protein kinase pathway in COS-7 cells. *J Biol Chem* **269**: 7851–7854, 1994.
15. Ramirez I, Tebar F, Grau M and Soley M, Role of heterotrimeric G-proteins in epidermal growth factor signalling. *Cell Signal* **7**: 303–311, 1995.
16. van Biesen T, Luttrell LM, Hawes BE and Lefkowitz RJ, Mitogenic signaling via G protein-coupled receptors. *Endocr Rev* **17**: 698–714, 1996.
17. van Biesen T, Hawes BE, Luttrell DK, Krueger KM, Touhara K, Porfirio E, Sakaue M, Luttrell LM and Lefkowitz RJ,

- Receptor-tyrosine-kinase- and G $\beta\gamma$ -mediated MAP kinase activation by a common signalling pathway. *Nature* **376**: 781–784, 1995.
18. Leduc I, Haddad P, Giasson E and Meloche S, Involvement of a tyrosine kinase pathway in the growth-promoting effects of angiotensin II on aortic smooth muscle cells. *Mol Pharmacol* **48**: 582–592, 1995.
 19. Wan Y, Kurosaki T and Huang XY, Tyrosine kinases in activation of the MAP kinase cascade by G-protein-coupled receptors. *Nature* **380**: 541–544, 1996.
 20. Earp HS, Huckle WR, Dawson TL, Li X, Graves LM and Dy R, Angiotensin II activates at least two tyrosine kinases in rat liver epithelial cells: Separation of the major calcium-regulated tyrosine kinase from p125^{FAK}. *J Biol Chem* **270**: 28440–28447, 1995.
 21. Zohn IE, Yu H, Li X, Cox AD and Earp HS, Angiotensin II stimulates calcium-dependent activation of c-Jun N-terminal kinase. *Mol Cell Biol* **15**: 6160–6168, 1995.
 22. Guo Y-L, Peng M, Kang B and Williamson JR, Inhibition of thrombin-stimulated cell proliferation by ceramide is not through inhibition of extracellular signal-regulated protein kinase. *Biochem Biophys Res Commun* **240**: 405–408, 1997.
 23. Bradford MM, A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. *Anal Biochem* **72**: 248–254, 1976.
 24. Qiu Z-H and Leslie CC, Protein kinase C-dependent and -independent pathways of mitogen-activated protein kinase activation in macrophages by stimuli that activate phospholipase A₂. *J Biol Chem* **269**: 19480–19487, 1994.
 25. Tsygankova OM, Peng M, Maloney JA, Hopkins N and Williamson JR, Angiotensin II induces diverse signal transduction pathways via both G_q and G_i proteins in liver epithelial cells. *J Cell Biochem* **69**: 63–71, 1998.
 26. Baffy G, Sharma K, Shi W, Ziyadeh FN and Williamson JR, Growth arrest of a murine mesangial cell line by transforming growth factor β 1 is associated with inhibition of mitogen-induced Ca²⁺ mobilization. *Biochem Biophys Res Commun* **210**: 378–383, 1995.
 27. Sun H, Tonks NK and Bar-Sagi D, Inhibition of Ras-induced DNA synthesis by expression of the phosphatase MKP-1. *Science* **266**: 285–288, 1994.
 28. Hug H and Sarre TF, Protein kinase C isoenzymes: Divergence in signal transduction? *Biochem J* **291**: 329–343, 1993.
 29. Maloney JA, Tsygankova OM, Szot A, Yang L, Li Q and Williamson JR, Differential translocation of protein kinase C isozymes by phorbol esters, EGF, and ANG II in rat liver WB cells. *Am J Physiol* **274**: C974–C982, 1998.
 30. Rhee SG and Bae YS, Regulation of phosphoinositide-specific phospholipase C isozymes. *J Biol Chem* **272**: 15045–15048, 1997.
 31. Howe LR and Marshall CJ, Lysophosphatidic acid stimulates mitogen-activated protein kinase activation via a G-protein-coupled pathway requiring p21^{ras} and p74^{raf-1}. *J Biol Chem* **268**: 20717–20720, 1993.
 32. Winitz S, Russell M, Qian N-X, Gardner A, Dwyer L and Johnson GL, Involvement of Ras and Raf in the G_i-coupled acetylcholine muscarinic m2 receptor activation of mitogen-activated protein (MAP) kinase and MAP kinase. *J Biol Chem* **268**: 19196–19199, 1993.
 33. Crespo P, Xu N, Daniotti JL, Troppmair J, Rapp UR and Gutkind JS, Signaling through transforming G protein-coupled receptors in NIH 3T3 cells involves c-Raf activation. *J Biol Chem* **269**: 21103–21109, 1994.
 34. Koch WJ, Hawes BE, Allen LF and Lefkowitz RJ, Direct evidence that G_i-coupled receptor stimulation of mitogen-activated protein kinase is mediated by G _{$\beta\gamma$} activation of p21^{ras}. *Proc Natl Acad Sci USA* **91**: 12706–12710, 1994.
 35. Chao TSO, Foster DA, Rapp UR and Rosner MR, Differential Raf requirement for activation of mitogen-activated protein kinase by growth factors, phorbol esters, and calcium. *J Biol Chem* **269**: 7337–7341, 1994.
 36. Dikic I, Tokiwa G, Lev S, Courtneidge SA and Schlessinger J, A role for Pyk2 and Src in linking G-protein-coupled receptors with MAP kinase activation. *Nature* **383**: 547–550, 1996.
 37. Luttrell LM, Hawes BE, van Biesen T, Luttrell DK, Lansing TJ and Lefkowitz RJ, Role of c-Src tyrosine kinase in G protein-coupled receptor and G $\beta\gamma$ subunit-mediated activation of mitogen-activated protein kinases. *J Biol Chem* **271**: 19443–19450, 1996.
 38. Lev S, Moreno H, Martinez R, Canoll P, Peles E, Musacchio JM, Plowman GD, Rudy B and Schlessinger J, Protein tyrosine kinase PYK2 involved in Ca²⁺-induced regulation of ion channel and MAP kinase functions. *Nature* **376**: 737–745, 1995.
 39. Eguchi S, Matsumoto T, Motley ED, Utsunomiya H and Inagami T, Identification of an essential signaling cascade for mitogen-activated protein kinase activation by angiotensin II in cultured rat vascular smooth muscle cells. *J Biol Chem* **271**: 14169–14175, 1996.
 40. Sadoshima J, Qiu Z, Morgan JP and Izumo S, Angiotensin II and other hypertrophic stimuli mediated by G protein-coupled receptors activate tyrosine kinase, mitogen-activated protein kinase, and 90-kDa S6 kinase in cardiac myocytes: The critical role of Ca²⁺ dependent signaling. *Circ Res* **76**: 1–15, 1995.
 41. Wang J, Auger KR, Jarvis L, Shi Y and Roberts TM, Direct association of Grb2 with the p85 subunit of phosphatidylinositol 3-kinase. *J Biol Chem* **270**: 12774–12780, 1995.
 42. Wan Y, Bence K, Hata A, Kurosaki T, Veillette A and Huang XY, Genetic evidence for a tyrosine kinase cascade preceding the mitogen-activated protein kinase cascade in vertebrate G-protein signaling. *J Biol Chem* **272**: 17209–17215, 1997.